The Association between Allergies and Hematologic Tumors — A Review
DOI:
https://doi.org/10.12775/JEHS.2024.71.56110Keywords
hematologic tumors, allergy, atopy, Hodgkin lymphoma, non-Hodgkin's lymphoma, leukemiaAbstract
Introduction: Dysfunctions of the immune system in allergic diseases and hematological malignancies are the subject of many studies due to the mechanisms that link them. Chronic inflammation created in the immune response in an allergic reaction has been associated with developing neoplastic diseases.
Aim of the study: This review examines the potential correlation between Allergies and Hematologic Tumors: acute lymphoblastic leukemia, childhood leukemias, non-Hodgkin and Hodgkin lymphomas.
Material and methods: An English-language literature review was conducted, analyzing studies from the PubMed database up to October 2024 regarding the correlation between Allergies and Hematologic Tumors. The review was performed using the PubMed database, with 50 works used.
Conclusions: The relationship between allergies and hematological tumors is unclear. According to some studies, this relationship does not exist; some state, however, that allergic diseases show correlations with hematological malignancies. The results of these studies do not provide a clear answer to whether this is a positive or negative relationship. Some studies suggest that allergies reduce the risk of hematological malignancies, while others contradict this, suggesting that allergies may increase the risk of hematological tumors. The results of studies showing an increased risk of hematological malignancies in people suffering from allergies can be due to the hypothesis of antigenic stimulation, which may explain the mechanism of correlation between those diseases. This hypothesis suggests that chronic immune stimulation predisposes to hematologic malignancies such as multiple myeloma, non-Hodgkin's lymphoma (NHL), and leukemia by promoting the development of randomly occurring pro-oncogenic mutations in actively dividing immune cells. Different results on this potential correlation showed that further studies are necessary.
References
McCraw AJ, Chauhan J, Bax HJ, et al. Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. Cancers (Basel). 2021;13(17):4460. Published 2021 Sep 4. https://doi.org/10.3390/cancers13174460
Huanosta-Murillo E, Alcántara-Hernández M, Hernández-Rico B, et al. NLRP3 Regulates IL-4 Expression in TOX+ CD4+ T Cells of Cutaneous T Cell Lymphoma to Potentially Promote Disease Progression. Front Immunol. 2021;12:668369. Published 2021 Jun 16. https://doi.org/10.3389/fimmu.2021.668369
Ryan JJ, Morales JK, Falanga YT, Fernando JF, Macey MR. Mast cell regulation of the immune response [published correction appears in World Allergy Organ J. 2010 Jan;3(1):14]. World Allergy Organ J. 2009;2(10):224-232. https://doi.org/10.1097/WOX.0b013e3181c2a95e
Portelli MA, Hodge E, Sayers I. Genetic risk factors for the development of allergic disease identified by genome-wide association. Clin Exp Allergy. 2015;45(1):21-31.https://doi.org/10.1111/cea.12327
Tirado-Rodríguez B, Huerta-Yépez S. Allergies: diseases closely related to cancer. Bol Med Hosp Infant Mex. 2016;73(6):432-445. https://doi.org/10.1016/j.bmhimx.2016.11.006
Musolino C, Allegra A, Minciullo PL, Gangemi S. Allergy and risk of hematologic malignancies: associations and mechanisms. Leuk Res. 2014;38(10):1137-1144. https://doi.org/10.1016/j.leukres.2014.08.004
Chennamadhavuni A, Lyengar V, Mukkamalla SKR, Shimanovsky A. Leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 17, 2023.
Zekavat OR, Nikpendar E, Haghpanah S, Shokrgozar N, Dehghani SJ, Arandi N. Atopy manifestations in pediatric patients with acute lymphoblastic leukemia: correlation assessment with interleukin-4 (IL-4) and IgE level. BMC Pediatr. 2022;22(1):149. Published 2022 Mar 21. https://doi.org/10.1186/s12887-022-03216-2
Chang JH, Poppe MM, Hua CH, Marcus KJ, Esiashvili N. Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68 Suppl 2:e28371. https://doi.org/10.1002/pbc.28371
Wallace AD, Francis SS, Ma X, et al. Allergies and Childhood Acute Lymphoblastic Leukemia: A Case-Control Study and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2018;27(10):1142-1150. https://doi.org/10.1158/1055-9965.EPI-17-0584
Lariou MS, Dikalioti SK, Dessypris N, et al. Allergy and risk of acute lymphoblastic leukemia among children: a nationwide case control study in Greece. Cancer Epidemiol. 2013;37(2):146-151. https://doi.org/10.1016/j.canep.2012.10.012
Khosravi S, Mousavi-Fatemi K, Ebrahimi P, Barary M, Sio TT, Pirzaman AT. B-cell acute lymphoblastic leukemia associated with hypereosinophilia: a case report and brief literature review. SAGE Open Med Case Rep. 2024;12:2050313X241229592. Published 2024 Jan 31. https://doi.org/10.1177/2050313X241229592
da Conceição Nunes J, de Araujo GV, Viana MT, Sarinho ES. Association of atopic diseases and parvovirus B19 with acute lymphoblastic leukemia in childhood and adolescence in the northeast of Brazil. Int J Clin Oncol. 2016;21(5):989-995. https://doi.org/10.1007/s10147-016-0988-7
Atmaj E, Schuiling-Veninga CCM, van Tuinen EL, Bos JHJ, de Vries TW. The relationship between childhood leukaemia and childhood asthma: A pharmacoepidemiological study from the Netherlands. Pediatr Blood Cancer. 2023;70(4):e30231. https://doi.org/10.1002/pbc.30231
Renke J, Wasilewska E, Kędzierska-Mieszkowska S, et al. Tumor Suppressors-HTRA Proteases and Interleukin-12-in Pediatric Asthma and Allergic Rhinitis Patients. Medicina (Kaunas). 2020;56(6):298. Published 2020 Jun 17. https://doi.org/10.3390/medicina56060298
Ajrouche R, Chandab G, Petit A, et al. Allergies, genetic polymorphisms of Th2 interleukins, and childhood acute lymphoblastic leukemia: The ESTELLE study. Pediatr Blood Cancer. 2022;69(3):e29402. https://doi.org/10.1002/pbc.29402
Juliusson G, Hough R. Leukemia. Prog Tumor Res. 2016;43:87-100. https://doi.org/10.1159/000447076
Bispo JAB, Pinheiro PS, Kobetz EK. Epidemiology and Etiology of Leukemia and Lymphoma. Cold Spring Harb Perspect Med. 2020;10(6):a034819. Published 2020 Jun 1. https://doi.org/10.1101/cshperspect.a034819
Bloodworth MH, Rusznak M, Bastarache L, Wang J, Denny JC, Peebles RS Jr. Association of ST2 polymorphisms with atopy, asthma, and leukemia. J Allergy Clin Immunol. 2018;142(3):991-993.e3. https://doi.org/10.1016/j.jaci.2018.03.020
Buchbinder D, Kirov I, Danielson J, et al. Compound Heterozygous DOCK8 Mutations in a Patient with B Lymphoblastic Leukemia and EBV-Associated Diffuse Large B Cell Lymphoma. J Clin Immunol. 2019;39(6):592-595. https://doi.org/10.1007/s10875-019-00663-y
Renner ED, Puck JM, Holland SM, et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr. 2004;144(1):93-99. https://doi.org/10.1016/S0022-3476(03)00449-9
Gardikioti A, Venou TM, Mainou M, et al. Eosinophilic dermatosis in a patient with chronic lymphocytic leukemia: a rare case report. Acta Dermatovenerol Alp Pannonica Adriat. 2021;30(4):161-164.
Cohen PR. Hematologic-Related Malignancy-Induced Eosinophilic Dermatosis (He Remained): An eosinophilic dermatosis predominantly associated with chronic lymphocytic leukemia. J Am Acad Dermatol. 2020;82(1):e13-e14. https://doi.org/10.1016/j.jaad.2019.08.062
Rajput CD, Nikam BP, Malani SS. Paraneoplastic Eosinophilic Dermatosis in a Case of Chronic Lymphocytic Leukemia. Indian Dermatol Online J. 2019;10(1):61-63. https://doi.org/10.4103/idoj.IDOJ_121_18
Jin A, Pousti BT, Savage KT, Mollanazar NK, Lee JB, Hsu S. Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia. JAAD Case Rep. 2019;5(9):815-817. Published 2019 Aug 30. https://doi.org/10.1016/j.jdcr.2019.07.026
Sapkota S, Shaikh H. Non-Hodgkin Lymphoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 24, 2023.
Singh R, Shaik S, Negi BS, et al. Non-Hodgkin's lymphoma: A review. J Family Med Prim Care. 2020;9(4):1834-1840. Published 2020 Apr 30. https://doi.org/10.4103/jfmpc.jfmpc_1037_19
Hofmann JN, Hoppin JA, Lynch CF, et al. Farm characteristics, allergy symptoms, and risk of non-hodgkin lymphoid neoplasms in the agricultural health study. Cancer Epidemiol Biomarkers Prev. 2015;24(3):587-594.https://doi.org/10.1158/1055-9965.EPI-14-1246
Wang J, Mack TM, Hamilton AS, et al. Common immune-related exposures/conditions and risk of non-Hodgkin lymphoma: a case-control study of disease-discordant twin pairs. Am J Epidemiol. 2015;182(5):417-425. https://doi.org/10.1093/aje/kwv053
Yang J, Xu H, Liang X, Lv S, Lin B, Jia Y. Allergic conditions are not associated with the risk of non-Hodgkin's lymphoma or Hodgkin's lymphoma: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:2189-2198. Published 2017 Apr 18. https://doi.org/10.2147/OTT.S128849
Fabbro-Peray P, Daures JP, Rossi JF. Environmental risk factors for non-Hodgkin's lymphoma: a population-based case-control study in Languedoc-Roussillon, France. Cancer Causes Control. 2001;12(3):201-212. https://doi.org/10.1023/a:1011274922701
Mansfield KE, Schmidt SAJ, Darvalics B, et al. Association Between Atopic Eczema and Cancer in England and Denmark. JAMA Dermatol. 2020;156(10):1086-1097. https://doi.org/10.1001/jamadermatol.2020.1948
Nieters A, Łuczyńska A, Becker S, et al. Prediagnostic immunoglobulin E levels and risk of chronic lymphocytic leukemia, other lymphomas and multiple myeloma-results of the European Prospective Investigation into Cancer and Nutrition. Carcinogenesis. 2014;35(12):2716-2722. https://doi.org/10.1093/carcin/bgu188
Briggs NC, Levine RS, Brann EA. Allergies and risk of non-Hodgkin's lymphoma by subtype. Cancer Epidemiol Biomarkers Prev. 2002;11(4):401-407.
Jencks A, Kiavash K, Daveluy S, Thompson AD. Eosinophilic Dermatosis of Myeloproliferative Disease in a Young Adult With Diffuse Large B-Cell Lymphoma. Am J Dermatopathol. 2019;41(4):303-308. https://doi.org/10.1097/DAD.0000000000001256
Yang J, Xu H, Liang X, Lv S, Lin B, Jia Y. Allergic conditions are not associated with the risk of non-Hodgkin's lymphoma or Hodgkin's lymphoma: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:2189-2198. Published 2017 Apr 18. https://doi.org/10.2147/OTT.S128849
Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet. 2021;398(10310):1518-1527. https://doi.org/10.1016/S0140-6736(20)32207-8
Rafiq M, Hayward A, Warren-Gash C, et al. Allergic disease, corticosteroid use, and risk of Hodgkin lymphoma: A United Kingdom nationwide case-control study. J Allergy Clin Immunol. 2020;145(3):868-876. https://doi.org/10.1016/j.jaci.2019.10.033
Link BK. Immunologic dysfunction and Hodgkin lymphoma: Insight to better therapy?. J Allergy Clin Immunol. 2020;145(3):780-781. https://doi.org/10.1016/j.jaci.2019.12.914
Whiteside S, Markova M, Chin A, et al. Influence of Chemotherapy on Allergen-Specific IgE. Int Arch Allergy Immunol. 2018;177(2):145-152. https://doi.org/10.1159/000489706
McCraw AJ, Chauhan J, Bax HJ, et al. Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. Cancers (Basel). 2021;13(17):4460. Published 2021 Sep 4. https://doi.org/10.3390/cancers13174460
Pagani M, Bavbek S, Alvarez-Cuesta E, et al. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper. Allergy. 2022;77(2):388-403. https://doi.org/10.1111/all.15113
Rau RE, Dreyer Z, Choi MR, et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018;65(3):10.1002/pbc.26873. https://doi.org/10.1002/pbc.26873
Sandley M, Angus J. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management. Leuk Lymphoma. 2023;64(4):776-787.
Burke MJ, Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. Future Oncol. 2022;18(10):1285-1299. https://doi.org/10.2217/fon-2021-1288
Hudson MM, Weinstein HJ, Donaldson SS, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol. 1993;11(6):1080-1084. https://doi.org/10.1200/JCO.1993.11.6.1080
Kellie SJ, Crist WM, Pui CH, et al. Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia. Cancer. 1991;67(4):1070-1075. https://doi.org/10.1002/1097-0142(19910215)67:4<1070::AID-CNCR2820670434>3.0.CO;2-X
Stockton WM, Nguyen T, Zhang L, Dowling TC. Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies. J Oncol Pharm Pract. 2020;26(2):397-405. https://doi.org/10.1177/1078155219858390
Polistena P, Tran Q, Cirillo M, O'Sullivan M, Purtill D. Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma. Bone Marrow Transplant. 2017;52(3):455-456. https://doi.org/10.1038/bmt.2016.288
Cotteret C, Rousseau J, Zribi K, Schlatter J. Severe hypersensitivity reaction to etoposide phosphate: A case report. Clin Case Rep. 2020;8(9):1821-1823. Published 2020 Aug 6. https://doi.org/10.1002/ccr3.2732
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aleksandra Hrapkowicz, Joanna Szydziak, Kinga Janowska, Olga Szeidl, Dominika Rehan, Julia Wołoszczak, Agnieszka Mioskowska , Daria Dąbkowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 156
Number of citations: 0
